<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425773</url>
  </required_header>
  <id_info>
    <org_study_id>BVAC-B-P1</org_study_id>
    <nct_id>NCT03425773</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care</brief_title>
  <acronym>BVAC-B</acronym>
  <official_title>Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellid Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellid Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BVAC-B is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell.
      This study is Open-label, Accelerated titration, Multiple dosing study to evaluate the
      safety, tolerability, immune response and pre-efficacy of BVAC-B in patients with progressive
      or recurrent HER2/neu positive gastric cancer after failure to standard care. 9-27 patients
      will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 13, 2018</start_date>
  <completion_date type="Anticipated">June 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Accelerated titration</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Maximum tolerated dose(MTD) for phase 2 trial</measure>
    <time_frame>End of Dose-escalation stage(7 month from study start, Estimated)</time_frame>
    <description>Find Serious adverse drug reaction(Grade 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events assessed with CTCAE v4.03</measure>
    <time_frame>14th week from first injection</time_frame>
    <description>Evaluate safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine</measure>
    <time_frame>Screening visit, Visit 2 (0 week) , visit 4 (4 week) ,visit 5 (6 week), visit 6 (8 week), visit 8(12 week), Termination visit(16 week)</time_frame>
    <description>Measure Interferon(IFN)-r, Interleukin(IL)-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER2/neu specific antibody</measure>
    <time_frame>Screening visit, every 2 weeks after 1st injection(till 16th week)</time_frame>
    <description>Measure HER2/neu specific antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NKT/NK cell assay</measure>
    <time_frame>Screening visit, every 24hr after injection(up to 12th week)</time_frame>
    <description>Measure NKT/NK cell activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4/CD8 assay</measure>
    <time_frame>Screening visit, every 2 weeks after 1st injection(up to 16th week)</time_frame>
    <description>Measure CD4/CD8 T cell activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte subset</measure>
    <time_frame>Screening visit, visit 4 (4 week), visit 6 (8 week), visit 8 (12 week), termination visit (16 week)</time_frame>
    <description>Measure change of lymphocyte subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tumor burden</measure>
    <time_frame>Screening visit, Termination visit(16th week)</time_frame>
    <description>Measure change of tumor burden by CT/MRI to determine pre-effecacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>BVAC-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BVAC-B IV injection at 0, 4, 8, 12nd weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BVAC-B</intervention_name>
    <description>Autologous B cell and monocyte presenting HER2/neu antigen</description>
    <arm_group_label>BVAC-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Progressive or recurrent HER2/neu positive(IHC 1+â‰¥) gastric cancer

          -  Received 1 or more chemotherapy or radiotherapy as prior therapy for progressive or
             recurrent tumor lesion

          -  At least 1 measurable lesion according to RECIST(ver 1.1)

          -  Ages above 19

          -  ECOG performance status between 0 to 2

          -  Patients meets the blood test standards in the screening test

          -  Patients meets the blood chemistry test standards in the screening test

          -  Patients who has agreed to a medically accepted contraceptive in this clinical trial

          -  Patients at least six months or more of survival can be expected

          -  Patients decided to participate in this clinical trial and signed written informed
             consent

        Exclusion Criteria:

          -  Histopathology is a neuroendocrine or small cell carcinoma

          -  History of brain metastasis or signs of brain metastasis

          -  Clinical diagnosis of hepatitis C or hepatitis B

          -  Clinical diagnosis of human immunodeficiency virus (HIV)

          -  History of HIV infection

          -  Patients with heart failure, coronary artery disease(CAD) or Myocardial infarction in
             6 month prior to screening. (LVEF is lower than 50% in screening visit)

          -  Administered the drug for other clinical trials within 4weeks before participate in
             this trial

          -  Administered any vaccines within 4weeks before participate in this trial (4 weeks for
             live vaccine, 2 weeks for other inactivated vaccine)

          -  Administered the granulocytes concentrates within 3 months before the screening visit

          -  Received chemotherapy or radiation therapy within 2 weeks before the 1st
             administration of investigational drug(BVAC-B)

          -  Received following formulation within 1 months before the screening visit : Chronic
             steroids(more than 5 days), immunosuppressant or immunomodulatory agents. G-CSF

          -  Patients who have participated in the clinical trial of a immunotherapeutic vaccine
             within 1 year or immunotherapy within 3 months before the screening visit

          -  Patients who is pregnant or breast-feeding

          -  Patients who researchers has determined that participation in the clinical trial is
             inappropriate

          -  Suspected to have other progressive cancer or malignant tumor needs treatment in 3
             years. Completely treated basal cell carcinoma of the skin, squamous cell carcinoma of
             the skin, thyroid carcinoma, cervical intraepithelial neoplasia are not included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu Hyun Kim, DVM</last_name>
    <phone>+82-2-3285-7861</phone>
    <email>whkim@cellid.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>T G Oh, ph.D</last_name>
    <phone>+82-2-3285-7861</phone>
    <email>whkim@cellid.co.kr</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2/neu</keyword>
  <keyword>IHC 1+</keyword>
  <keyword>BVAC</keyword>
  <keyword>Cellid</keyword>
  <keyword>B-cell</keyword>
  <keyword>Monocyte</keyword>
  <keyword>Immunotherapeutic vaccine</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

